Post by
ZakDixon on Nov 19, 2021 12:11pm
BioSyent Q3 Results
BioSyent Inc. is on a trajectory to grow double digit over the next few years. It is very conservative with capital deployment but suspect with the $27 million in cash it is going to be forced to deploy the capital a little more aggressively that it traditionally has. If that happens it will grow with enormous gross margins of 78%+ and that is most likely to drop down to the bottom line. It is also spending a lot on promoting its 2 new products Tibolone and Combogesic, a combination of two very popular OTC medications into one. Though it has begun to advertise aggressively, its ability to tell doctors about these meds is better than spending millions on advertising.